Opthea Limited (NASDAQ:OPT - Get Free Report) shares saw strong trading volume on Friday . 30,043 shares traded hands during mid-day trading, an increase of 19% from the previous session's volume of 25,264 shares.The stock last traded at $3.51 and had previously closed at $3.52.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on OPT shares. Canaccord Genuity Group raised Opthea to a "strong-buy" rating in a research note on Tuesday, December 17th. HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Opthea in a report on Friday, February 28th.
Read Our Latest Stock Analysis on Opthea
Opthea Stock Performance
The stock's 50-day moving average is $4.52 and its 200-day moving average is $4.05.
Institutional Investors Weigh In On Opthea
Several hedge funds have recently made changes to their positions in the business. Jane Street Group LLC purchased a new position in Opthea during the third quarter worth about $114,000. Twin Lakes Capital Management LLC acquired a new position in shares of Opthea during the 3rd quarter valued at about $81,000. ABC Arbitrage SA purchased a new position in shares of Opthea during the 4th quarter worth about $40,000. OLD Mission Capital LLC acquired a new stake in shares of Opthea in the fourth quarter worth approximately $42,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Opthea in the fourth quarter worth approximately $556,000. Institutional investors and hedge funds own 55.95% of the company's stock.
About Opthea
(
Get Free Report)
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
See Also
Before you consider Opthea, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.
While Opthea currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
